Research has indicated that increased m1A modification in bladder cancer is closely linked to the abnormal expression of TRMT6/61A, which controls the target mRNA unfolded protein response (UPR) and bladder cancer advancement through tRF-3B (Li et al., 2022a). The gene discussed is TRMT6; the disease is urinary bladder carcinoma.